Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
19/09/2025
Takashi Hayana: Fiscal stimulus measures will increase income levels and improve consumer sentiment.
Latest
2 m ago
Bank of Japan Governor Haruhiko Kuroda: The economy still faces downside risks.
2 m ago
Pharmaron Health-B continues to decline, with intraday losses expanding to 16.6%, closing at 152.9 Hong Kong dollars.
2 m ago
Every AI Quick News, Open Source Securities released a research report on September 19th giving Source Jie Technology (688498.SH) a buy rating. The rating reasons mainly include: 1) Leading domestic optoelectronic chip company, recognized by mainstream customers, may benefit deeply from the development of AI + GC; 2) Rapid development of AI computing power industry, broad prospects for optoelectronic chip market. (Daily Economic News)
2 m ago
Novo Nordisk announced multiple research results at the 2025 annual meeting of the European Association for the Study of Diabetes (EASD). Among them, the STEP UP trial showed that participants receiving higher doses of semaglutide (7.2 mg weight loss version) achieved an average weight loss of 21% compared to the placebo group, with one-third of participants experiencing a weight loss of 25% or more. In the STEP UP trial, 84.5% of the weight loss achieved with semaglutide 7.2 mg was attributed to fat reduction. Subgroup analysis results from the STEP UP trial showed no significant differences in lean body weight and muscle mass changes in participants receiving semaglutide 7.2 mg compared to the placebo group, and muscle function was also preserved.
3 m ago
JPMorgan Chase: Raised Amphenol's target price from $46.00 to $53.00.
See all latest
